Detailed Information

Cited 2 time in webofscience Cited 2 time in scopus
Metadata Downloads

A global epidemiological analysis of COVID-19 vaccine types and clinical outcomesopen access

Authors
Alhinai, ZaidPark, SangshinChoe, Young-JuneMichelow, Ian C.
Issue Date
Nov-2022
Publisher
Elsevier BV
Keywords
SARS-CoV-2; COVID-19 vaccine; mRNA vaccine; Adenovirus vaccine; Inactivated virus vaccine; Comparative effectiveness
Citation
International Journal of Infectious Diseases, v.124, pp 206 - 211
Pages
6
Indexed
SCIE
SCOPUS
Journal Title
International Journal of Infectious Diseases
Volume
124
Start Page
206
End Page
211
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/61808
DOI
10.1016/j.ijid.2022.09.014
ISSN
1201-9712
1878-3511
Abstract
Objectives To compare messenger RNA (mRNA)–based and adenovirus-vectored vaccines (ADVVs) with inactivated virus vaccines (IVVs) using real-world aggregate data. Methods We performed longitudinal analyses of publicly accessible epidemiological, clinical, virological, vaccine-related, and other public health data from 41 eligible countries during the first half of 2021. The relationships between vaccination coverage and clinical outcomes were analyzed using repeated measures correlation analyses and mixed-effects modeling to adjust for potential mediating and confounding factors. Results Countries that used mRNA and/or ADVV (n = 31) vs IVV, among other vaccine types (n = 10), had different distributions of age (42.4 vs 33.9 years, respectively; P-value = 0.0006), gross domestic product per capita ($ 38,606 vs $ 20,422, respectively; P <0.0001), and population sizes (8,655,541 vs 5,139,162, respectively; P-value = 0.36). After adjustment for country differences, the stringency of nonpharmaceutical interventions, and dominant SARS-CoV-2 variant types, populations that received mRNA and/or ADVV had significantly lower rates of cases and deaths over time (P <0.001 for each analysis). Populations vaccinated with IVV, among others, had significantly higher rates of cases and deaths over time (P <0.05 for each analysis). Conclusion The real-world effectiveness of IVV may be inferior to mRNA and/or ADVV, and prospective comparative studies are needed to critically evaluate the role of IVV in the context of contemporary SARS-CoV-2 variants.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Pediatrics > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Choe, Young June photo

Choe, Young June
Anam Hospital (Department of Pediatrics, Anam Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE